Indiana Hemophilia & Thrombosis Center, Inc.

FDA Approves Novo Nordisk's Alhemo for Hemophilia A and B with Inhibitors

5 months ago

• The FDA has approved Alhemo (concizumab-mtci) as a once-daily prophylactic treatment for hemophilia A and B with inhibitors in patients 12 years and older. • Alhemo, a subcutaneous injection, is the first of its kind for this patient population, offering an alternative to intravenous infusions. • Clinical trials showed an 86% reduction in treated bleeding episodes with Alhemo compared to no prophylaxis, significantly improving patient outcomes. • Alhemo works by blocking tissue factor pathway inhibitor (TFPI), enhancing thrombin production to facilitate blood clotting in the presence of inhibitors.